Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference

Core Insights - Sutro Biopharma, Inc. is participating in the 16th Annual World ADC Conference, showcasing its advancements in antibody-drug conjugates (ADCs) [1][2] - The company aims to present new preclinical data that highlights its innovative dual-payload ADCs, which may redefine treatment paradigms in oncology by enhancing therapeutic index and addressing tumor resistance [2][6] Company Overview - Sutro Biopharma is focused on advancing a next-generation ADC platform that delivers single- and dual-payload ADCs, targeting significant oncology markets with limited treatment options [5][6] - The company utilizes a cell-free platform to optimize the antibody, linker, and payload, aiming to improve drug exposure, reduce side effects, and expand treatable tumor types [6] Conference Presentation Details - Presentations at the conference include topics such as the development of site-specific dual-payload ADCs, immunostimulatory ADCs, and the advantages of cell-free antibody manufacturing [3][5] - Key presenters include Hans-Peter Gerber, Daniel Calerese, Gang Yin, Venkatesh Srinivasan, Krishna Bajjuri, and Alice Yam, discussing various aspects of ADC innovation and development [5] Future Directions - Sutro's commitment to driving long-term value through transformative science is reinforced by its focus on overcoming treatment resistance and redefining cancer therapy possibilities [2][6]